Bruker BioSciences Corp. (BRKR)

[Monksdream]

BRKR new 52 week hi

[stocktrademan]

$BRKR recent news/filings

bullish 24.35

## source: finance.yahoo.com

Wed, 16 Dec 2015 14:30:02 GMT ~ New Strong Buy Stocks for December 16th


read full: http://finance.yahoo.com/news/strong-buy-stocks-december-16th-143002947.html
*********************************************************

Mon, 14 Dec 2015 19:59:25 GMT ~ Bruker Introduces Vutara 352 Super-Resolution Fluorescence Microscope

[at noodls] - http://www.businesswire.com/news/home/20151214006237/en/ (Photo: Business Wire) The Vutara 352 is now also compatible with Bruker's Opterra multi-point confocal microscope, creating a unique combination ...

read full: http://www.noodls.com/view/4E32F687354F8DA7770A9ACDAFCB3B7681B6D913
*********************************************************

Mon, 14 Dec 2015 19:41:00 GMT ~ Bruker Introduces Vutara 352 Super-Resolution Fluorescence Microscope

[Business Wire] - At the 2015 Cell Biology ASCB Annual Meeting, Bruker today announced the release of the first quantitative super-resolution microscope, the Vutara™ 352. The Vutara 352 offers speed, imaging depth, and resolution to deliver significant advantages over competing approaches, now also adding real-time quantitative capabilities.

read full: http://finance.yahoo.com/news/bruker-introduces-vutara-352-super-194100485.html
*********************************************************

Fri, 11 Dec 2015 14:55:02 GMT ~ Bruker (BRKR) Stock: Moving Average Crossover Alert


read full: http://finance.yahoo.com/news/bruker-brkr-stock-moving-average-145502984.html
*********************************************************

Thu, 10 Dec 2015 19:20:07 GMT ~ Bruker (BRKR) Shows Balanced Growth: Add to Your Portfolio


read full: http://finance.yahoo.com/news/bruker-brkr-shows-balanced-growth-192007052.html
*********************************************************

$BRKR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$BRKR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/BRKR/company-info
Ticker: $BRKR
OTC Market Place: Not Available
CIK code: 0001109354
Company name: Bruker Corp.
Company website: http://www.daltonics.bruker.com
Incorporated In: DE, USA

$BRKR share structure

## source: otcmarkets.com

Market Value: $4,087,834,876 a/o Dec 24, 2015
Shares Outstanding: 167,878,229 a/o Nov 02, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$BRKR extra dd links

Company name: Bruker Corp.
Company website: http://www.daltonics.bruker.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BRKR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BRKR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BRKR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/news - http://finance.yahoo.com/q/h?s=BRKR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BRKR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BRKR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BRKR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Bruker+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Bruker+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Bruker+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.daltonics.bruker.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.daltonics.bruker.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.daltonics.bruker.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BRKR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001109354&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BRKR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BRKR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BRKR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BRKR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BRKR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BRKR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BRKR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BRKR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BRKR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BRKR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BRKR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BRKR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BRKR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BRKR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BRKR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BRKR



$BRKR DD Notes ~ http://www.ddnotesmaker.com/BRKR

[Renee]

BRKR SEC Admin Proceeding:

http://www.sec.gov/litigation/admin/2014/34-73835.pdf

[stocktrademan]

$BRKR recent news/filings

bullish optionable

## source: finance.yahoo.com

Fri, 08 Aug 2014 17:33:54 GMT ~ BRUKER CORP Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/140808/brkr10-q.html
*********************************************************

Thu, 07 Aug 2014 17:04:00 GMT ~ 3 Stocks Dragging The Electronics Industry Downward


read full: http://www.thestreet.com/story/12837761/1/3-stocks-dragging-the-electronics-industry-downward.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Wed, 06 Aug 2014 21:34:34 GMT ~ Bruker Reports Second Quarter 2014 Financial Results

[at noodls] - 08/06/2014 BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2014. ... This is an abstract of the original noodl. ...

read full: http://www.noodls.com/view/CEB3E2098C29E88E7E08AC01A2DB9401B595DCAC
*********************************************************

Wed, 06 Aug 2014 20:12:00 GMT ~ 4:12 pm Bruker Corp. beats by $0.02, reports revs in-line; lowers FY14 guidance


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#brkr
*********************************************************

Wed, 06 Aug 2014 20:04:47 GMT ~ BRUKER CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/140806/brkr8-k.html
*********************************************************


$BRKR charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$BRKR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/BRKR/company-info
Ticker: $BRKR
OTC Market Place: Not Available
CIK code: 0001109354
Company name: Bruker Corp.
Company website: http://www.daltonics.bruker.com
Incorporated In: DE, USA


$BRKR share structure

## source: otcmarkets.com

Market Value: $3,471,547,919 a/o Aug 07, 2014
Shares Outstanding: 167,869,822 a/o May 02, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$BRKR extra dd links

Company name: Bruker Corp.
Company website: http://www.daltonics.bruker.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BRKR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BRKR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BRKR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/news - http://finance.yahoo.com/q/h?s=BRKR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BRKR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BRKR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BRKR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Bruker+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Bruker+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Bruker+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.daltonics.bruker.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.daltonics.bruker.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.daltonics.bruker.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BRKR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001109354&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BRKR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BRKR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BRKR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BRKR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BRKR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BRKR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BRKR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BRKR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BRKR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BRKR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BRKR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BRKR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BRKR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BRKR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BRKR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BRKR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BRKR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BRKR



$BRKR DD Notes ~ http://www.ddnotesmaker.com/BRKR

[Penny Roger$]

~ Monday! $BRKR ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BRKR ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BRKR&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BRKR&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=BRKR
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BRKR#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BRKR+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BRKR
Finviz: http://finviz.com/quote.ashx?t=BRKR
~ BusyStock: http://busystock.com/i.php?s=BRKR&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=BRKR >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[wEaReLeGiOn]

Still holding better than most indexes :)

[wEaReLeGiOn]

These 52 week highs are hard to take :)

[wEaReLeGiOn]

Bruker Corporation to Release Fourth Quarter

http://ih.advfn.com/p.php?pid=nmona&article=41640405&symbol=BRKR

and Full Year 2009 Financial Results on February 25th, 2010
Date : 02/19/2010 @ 7:00AM
Source : Business Wire
Stock : Bruker Corporation (BRKR)
Quote : 13.38 -0.09 (-0.67%) @ 7:22AM


Bruker Corporation to Release Fourth Quarter and Full Year 2009 Financial Results on February 25th, 2010

Bruker Corporation (NASDAQ: BRKR) announced today that it plans to release its fourth quarter and fiscal year 2009 financial results on Thursday, February 25th, 2010 before the market opens. Bruker will then host an operator-assisted earnings conference call that morning at 9:00 AM Eastern Time. To listen to the webcast, investors can go to ir.bruker.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days.

Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796 or 617-614-4070 outside the US and Canada. Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call will be available approximately one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 24438469.

[MSC290]

Bruker Helps Haitian Relief Mission by Helping with Implant Metal Verification

Jan 24, 2010 - Azom News

http://www.azom.com/news.asp?NewsID=20428

Bruker Elemental contributes in-kind donation to assist local medical non-profit, Surgical Implant Generation Network (SIGN), in preparation of their Haitian relief mission. Bruker Elemental donated the use of a S1 TURBOSD handheld XRF analyzer to help identify and verify the metal alloys used in these medical implants. This form of positive material identification (PMI) is used to find counterfeit implants made of non-surgical steels.



SIGN, founded by Richland, WA orthopedic surgeon Dr. Lewis Zirkle, specializes in supplying orthopedic surgical kits to hospitals around the world. Their mission is 'to support surgeons in the developing nations by providing them with training and modern equipment so they can provide immediate surgical treatment to their patients. As a result, surgeons can treat more patients in a timely manner, and patients are soon able to walk and return to work to feed and care for their families.' Dr. Zirkle and the SIGN team are now on the ground in Haiti and working out of Kings Hospital in Port-au-Prince. Their blog is http://www.signhaiti.blogspot.com/

In addition to the use of a S1 TURBOSD for material identification, Bruker Elemental donated in-kind labor to help prepare the orthopedic materials for shipment to Haiti. Volunteers spent the afternoon sorting and packing kits of surgical instruments, screws, implants and other orthopedic trauma items.

[MSC290]

Bruker Corp. says Q4 revenues will beat both 2008 and analysts' expectations

January 13, 2010 - by MassDevice staff

Fourth-quarter revenues at Bruker Corp. are likely to beat its year-ago numbers and the expectations of analysts, according to a preliminary count by the Billerica, Mass.-based manufacturer of laboratory equipment.

http://www.massdevice.com/news/bruker-corp-says-q4-revenues-will-beat-both-2008-and-analysts-expectations

Bruker Corp. (NSDQ:BRKR) likely generated more than $340 million in revenues during the fourth quarter, beating both year-ago levels and consensus analyst opinion for the period, according to company officials.

The preliminary revenue figures for the three months ended Dec. 31, 2009, were reported Jan. 13 as part of an investor presentation by Bruker executives at the J.P. Morgan Healthcare Conference in San Francisco. During their prepared remarks, CEO Frank Laukien and chief accounting officer Brian Monahan said the firm finished 2009 with a "healthy" order backlog and is beginning to see a gradual recovery in industrial orders.

The estimated $340 million in fourth-quarter revenues would mark a $25 million, or 8 percent, jump from the year-ending quarter at Bruker in 2008. It also would beat the $329.4 million average of revenue forecasts by analysts tracking the Billerica, Mass-based manufacturer of research and laboratory equipment.

The year-end bounce, however, failed to lift total revenues for 2009 past 2008. For the 12 months ended Dec. 31, 2009, Bruker will likely record about $1.04 billion in revenues — or about $67 million below the $1.1 billion posted in 2008. The company will report its full financials in late February.

Laukien and Monahan also hoped to make news by announcing the imminent debut of its next-generation drug and explosive detection device. The detector builds on ion mobility spectrometry technology, which is able to detect trace amounts of materials by measuring the physical characteristics of gaseous ions and the speed they travel through a short tube to distinguish specific materials.

Neither story appeared to excite investors: Bruker stock was up 2 cents to $13.20 a share midway through Wednesday's market activity. The stock had slipped as low as $12.84 — a 3 percent decline — earlier in the day before recovering.

[MSC290]

X-ray technology has potential to transform archaeology

11 Jan, 2010 - The Armidale Express

A researcher at the University of New England is pioneering the use of new X-ray technology in analysing the composition of ancient pottery.

http://www.armidaleexpress.com.au/news/local/news/general/xray-technology-has-potential-to-transform-archaeology/1721945.aspx?storypage=1



On her retirement as a teacher of art and mathematics at Bairnsdale Secondary College in East Gippsland, Jesse Walker knew exactly what she wanted to do: study archaeology at the University of New England.

She didn’t know then, however, that her two-year honours program would involve her in exploring the use of X-ray fluorescence in archaeological research.

Archaeology and palaeoanthropology at UNE acquired a portable Bruker X-ray fluorescence (PXRF) instrument at the end of 2008, and when Ms Walker began her archaeology honours program in 2009 she was recognised - with her background in mathematics - as an ideal candidate to explore its capabilities in archaeology.

The PXRF instrument offers the exciting possibility of analysing the elemental composition of ancient ceramics without the necessity of destroying the material being analysed.

Its versatility opens new avenues for researchers, as they can now study valuable museum specimens without moving them to a laboratory.

The technology involves the analysis of ‘secondary’ (or fluorescent) X-rays emitted by a material that has been excited by bombarding it with high-energy X-rays.

It is used in a variety of

disciplines, including geochemistry, forensic science and archaeology, but its potential in the study of ceramics - particularly those housed in museums - has received little attention.

Ms Walker has at her disposal not only the PXRF instrument but also a museum well-endowed with ancient ceramics: UNE’s Museum of Antiquities, which celebrated its 50th anniversary last year.

Using a set of potsherds (fragments of broken pottery) of known composition available to her through an ARC-funded research project on Iron Age trade and exchange, Ms Walker has figured out how to make the x -ray instrument suitable for the analysis of ancient ceramics.

She has used this same technology to analyse the elemental composition of two small ceramic vessels in the museum, dating from the early Iron Age.

“Patterns of ceramic elements can be difficult to interpret because people alter the clay - for example, by adding sand - during the manufacturing process,” Ms Walker said.

Her work will continue in 2010, but she believes she has already demonstrated that the instrument has exciting potential in the study of ancient ceramics.

“The PXRF offers the possibility of widespread use in museum collections, allowing researchers to investigate the sources - and subsequent movements through trade and other human activities - of high-quality ceramics,” she said.

[MSC290]

Companies with Madison area operations also had a strong 2009

January 8, 2010 - By JUDY NEWMAN - Wisconsin State Journal

Several companies with significant operations in the Madison area also counted 2009 as a strong year for their stock.

http://host.madison.com/wsj/news/article_52e2d3a8-fca8-11de-b3ba-001cc4c03286.html

• Shares of Sears Holdings, parent company of Lands' End, Dodgeville, more than doubled, ending 2009 at $83.45, up 115 percent from their 2008 close at $38.87. Last Thursday, the stock topped $100 in trading during the day after Sears and several other retailers raised their projections for fourth-quarter profits.

Sales for retail companies overall were "surprisingly strong" for most of the year, said Todd Parrish, analyst with Robert W. Baird & Co., Milwaukee.

"Relative to the environment we're in, sales managed pretty well. There wasn't a desperate kind of unloading (merchandise)," Parrish said.

• Mattel, parent of American Girl, Middleton, saw a 25 percent gain, closing 2009 at $19.98, up from $16.00 a year earlier.

• Kraft, parent of Kraft/Oscar Mayer, Madison, inched up to $27.18 from the 2008 close of $26.85. The stock hit its 52-week low in March, when it fell to $20.81 a share.

• Shares of Bruker, whose Bruker AXS division is based in Fitchburg, tripled to $12.06, from $4.04 the year before. Bruker AXS makes analytical X-ray systems for scientists and researchers.

• Spectrum Brands was suspended from trading on the New York Stock Exchange in December 2008 after it fell in the range of pennies and got stuck there. After going through bankruptcy proceedings in 2009, the old stock was eliminated and new shares ended the year at $22.50.

[MSC290]

Bruker Receives More than 100 Systems Orders Tied to Stimulus Programs

January 07, 2010 - GenomeWeb staff reporter

http://www.genomeweb.com/proteomics/bruker-receives-more-100-systems-orders-tied-stimulus-programs

NEW YORK (GenomeWeb News) – Bruker today said that it has already received more than 100 systems orders associated with various global stimulus funding programs.

The firm said that all five of its operating divisions have received stimulus orders for instruments such as mass spectrometry, NMR, pre-clinical MRI, and X-ray. Bruker estimated the average selling prices of these orders were greater than $500,000 per system — and the total amount of stimulus orders it received in the second half of 2009 exceeded $70 million.

The Billerica, Mass.-based firm said that revenues from these orders would be recorded primarily in 2010 and into the first half of 2011. It also expects to receive additional orders from global stimulus programs during this year.

In September, Bruker said that global stimulus programs could contribute 5 percent — roughly $50 million — or greater revenue growth its core scientific business instruments business in 2010.

In early Thursday trade on the Nasdaq, shares of Bruker were up 2 percent at $13.35.

[wEaReLeGiOn]

Seems to be regrowing legs :) eom

[MSC290]

Max weighs in as new weapon against cheats

12-20-2009 - By BARRY LICHTER - Sunday Star Times - Sport Racing

Drug cheats beware – the racing laboratory has a new toy which will bust you in a millisecond.

http://www.stuff.co.nz/sport/racing/3179545/Max-weighs-in-as-new-weapon-against-cheats

It sits in NZ Racing Laboratory Services' new building in West Auckland, just along the corridor from the solid phase extraction robots dubbed Mr Ed, Phar Lap, Desmond and Tornado which have been extracting illegal drugs from samples since the 1990s.

The German-made machine, which we'll nickname Max because it has such a daunting name – it's a Bruker MaXis liquid chromatography ultra high resolution quadrupole time-of-flight mass spectrometer – cost the New Zealand Racing Board the best part of $800,000.

And with its just completed installation, our racing laboratory becomes one of the most advanced in the world, its state-of-the-art tool one which should make unscrupulous trainers very, very afraid.

"I feel like I've got a Ferrari," enthuses racing chemist and analyst Rob Howitt, as he explains the vital statistics of Max.

"We were the first racing lab in the world to apply high resolution technology to drug screening. Now we can expand this methodology with a far superior instrument."

The predecessor to Max, called the TOF, was bought in 2006. It took the laboratory, under the direction of head Dr Geoff Beresford, more than a year to develop high resolution methods for horse racing, tackling problems like dirtier urine and the need for increased sensitivity.

"Many of the major racing labs will be switching to high resolution techniques," says Howitt. "This is the sort of technology that will eventually make some of our older instruments redundant."

Max will take over the crucial job of routine screening the 8000 samples taken annually from the country's racing population of thoroughbreds, standardbreds and greyhounds.

Standing proudly amid his predecessors, with his 2.5m flight tube protruding between concrete beams in the ceiling, Max is in reality allowing the analysts to stage their own races – between molecules. The time it takes the molecules to reach the finish line allows the lab to accurately identify them.

What Max actually does is charge the molecules, suck them through a vacuum system, and very accurately measure their mass based on the time it takes them to travel from the bottom of the flight tube to the top and back again.

"A lot of compounds have the same nominal mass but this machine allows us to distinguish them by a mass difference equivalent to a couple of electrons," says Howitt.
Ad Feedback

Through a complex system of metal lenses, Max can measure compounds to an incredible accuracy of one one-thousandth of a mass unit, thanks to its ultra-high resolution.

For example, whereas conventional instruments would come up with a mass reading of 271, Max will spit out 271.0637, positively identifying, in one step, the compound as Nordazapam.

Previously, analysts had to smash the molecules apart and look at their fragmentation patterns, which often overlap, to distinguish them from the dozens of other compounds weighing around 271.

"We used to fingerprint them by smashing them up, now we just weigh them," says Howitt. "Instead of looking for different groups of drugs with different methods, we can now cover a vast array with one method, and look for a lot of things simultaneously."

But another real advantage of Max is it will allow more retrospective testing of samples when new designer drugs surface – a significant deterrent for potential drug cheats.

Because Max logs all readings and profiles samples, data can be reprocessed so analysts will be able to go straight to dodgy stored samples – meaning retesting of maybe 10 samples, rather than 2000.

Harness Racing New Zealand veterinary adviser Dr Andrew Grierson said the machine will be in full service for Christmas-New Year racing.

"The ability of the racing lab to detect things has been really souped up with this machine – it's incredibly sensitive and accurate."

Grierson said it would have no trouble picking up the drug at the centre of the latest fuss, Aminorex, a methamphetamine-like substance that metabolised from the sheep drench Levamisole.

As revealed in last week's Sunday Star-Times, HRNZ issued a warning to trainers to stop using the drench after nationwide intelligence that, instead of using it as a worming or immune system boost, cheats were using it as a go-fast.

"The methodology of testing for it had been difficult overseas, but this machine makes it easy.

"Nothing will get past it."

[MSC290]

NIH Funds Slow to Reach Vendors, But MS and Other Instrument Firms May Be First to Benefit, Report Says

December 17, 2009 - Genome Web

Citing Bruker and Illumina, instrument firms, including several mass spectrometry firms, have seen little stimulus funding so far and expect such funds not to impact their fourth-quarter earnings results, according to the report from Thomas Weisel Partners. However, the investment firm said that once recipients start spending the grants, instrument vendors could be "the biggest beneficiaries of the initial funding wave."

http://www.genomeweb.com/proteomics/nih-funds-slow-reach-vendors-ms-and-other-instrument-firms-may-be-first-benefit-

[wEaReLeGiOn]

Bruker Corporation (NASDAQ: BRKR) today reported financial

results for the third quarter ended September 30, 2009.

Lookin' good :)


Third Quarter 2009 Highlights

* Revenue $265.1 million
* GAAP Net Income $16.4 million
* GAAP EPS $0.10 per diluted share
* Free cash flow $14.2 million

Financial Results

In the third quarter of 2009, revenue was $265.1 million, an increase of 9.5% compared to revenue of $242.1 million in the third quarter of 2008. Excluding the effect of foreign currency translation, third quarter 2009 revenue increased 11.4% year-over-year. GAAP net income for the third quarter of 2009 was $16.4 million, or $0.10 per diluted share, compared to GAAP net income of $17.8 million, or $0.11 per diluted share, in the third quarter of 2008. Included in GAAP EPS in the third quarter of 2008 were (i) one-time tax benefits of $0.07 per diluted share and (ii) non-cash stock-based compensation expense of ($0.01) per diluted share. Included in GAAP EPS in the third quarter of 2009 was non-cash stock-based compensation expense of ($0.01) per diluted share.

For the nine months ended September 30, 2009, revenue was $748.1 million, a decrease of 5.5% compared to revenue of $791.9 million in the first three quarters of 2008. Excluding the effect of foreign currency translation, revenue for the nine months ended September 30, 2009 increased by 0.5% year-over-year. GAAP net income for the nine months ended September 30, 2009 was $37.7 million, or $0.23 per diluted share, compared to GAAP net income of $38.7 million, or $0.23 per diluted share, for the nine months ended September 30, 2008. Included in GAAP EPS for the nine months ended September 30, 2008 were (i) one-time tax benefits of $0.07 per diluted share, (ii) Bruker BioSpin acquisition related expenses of ($0.04) per diluted share, and (iii) non-cash stock-based compensation expense of ($0.02) per diluted share. Included in GAAP EPS for the nine months ended September 30, 2009 was non-cash stock-based compensation expense of ($0.02) per diluted share.

Free cash flow was $14.2 million in the third quarter of 2009, and $58.4 million for the nine months ended September 30, 2009, compared to a use of cash of ($11.9) million for the third quarter of 2008, and a use of cash of ($20.9) million for the nine months ended September 30, 2008. During the third quarter of 2009, Bruker repaid $19.3 million of debt, ending the quarter with cash and cash equivalents of $150.5 million, and net debt of $0.8 million, compared to net debt of $127.6 million at the end of the third quarter of 2008.

Comment and Outlook

Frank Laukien, Bruker’s President and CEO, commented: “We are pleased with our double-digit currency-adjusted third quarter 2009 year-over-year revenue growth, with our solid sequential improvements in revenue, operating margins and net income during the first three quarters of 2009, and with our strong free cash flow year-to-date. Our third quarter 2009 operating income increased more than 70% year-over-year, and our operating margin improved sequentially by 180 basis points, when compared to the second quarter 2009.”

Dr. Laukien continued: “During the third quarter we have seen positive sequential trends in bookings throughout the company, even in the divisions with a greater industrial markets exposure. We have also begun to see robust bookings from our academic and government customers who are benefiting from various global government stimulus programs. While we expect a strong fourth quarter of 2009, we believe that most of the anticipated positive revenue and margin effects from global stimulus orders will be reflected in Bruker’s financial results in 2010 and 2011.”

Segment Information

After Bruker’s acquisition of the ACCEL Research Instruments business on April 1, 2009, starting with the second quarter of 2009, Bruker has established two new reportable segments:

1) The Bruker Scientific Instruments (BSI) segment which consists of the four divisions Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics.

2) The Bruker Energy & Supercon Technologies (BEST) segment which combines the acquired ACCEL RI business, and the superconductor and supercon devices business, which was previously called Bruker Advanced Supercon, Inc.

Revenue in the BSI segment for the nine months ended September 30, 2009 was $716.5 million, compared to BSI revenue of $767.3 million for the nine months ended September 30, 2008. Excluding the effects of foreign currency translation, for the first nine months of 2009, BSI revenue decreased by 1.0% year-over-year. BSI net income for the nine months ended September 30, 2009 was $41.7 million, compared to $45.3 million for the nine months ended September 30, 2008. BSI earnings per diluted share for the nine months ended September 30, 2009 were $0.25, compared to $0.27 for the nine months ended September 30, 2008.

Revenue in the BEST segment for the nine months ended September 30, 2009 was $36.0 million, compared to BEST revenue of $32.5 million for the nine months ended September 30, 2008. Excluding the effects of foreign currency translation, for the first nine months of 2009, BEST revenue increased by 23.4% year-over-year. BEST net loss for the nine months ended September 30, 2009 was ($5.0) million, compared to a net loss of ($6.8) million for the nine months ended September 30, 2008. BEST loss per diluted share for the nine months ended September 30, 2009 was ($0.03), compared to ($0.04) for the nine months ended September 30, 2008.

Following at the end of this press release are reconciliations of certain non-GAAP measures presented in this release.

USE OF NON-GAAP FINANCIAL MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the measures of non-GAAP revenue, non-GAAP net income, non-GAAP EPS by reportable segment, and non-GAAP free cash flow for Bruker Corporation. We believe that such non-GAAP measures help investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included in this press release are not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying table. Specifically:

* Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the nine months ended September 30, 2009 and 2008
* Reconciliation of Free Cash Flow

EARNINGS CONFERENCE CALL

Bruker Corporation will host an operator-assisted earnings conference call at 9:00 a.m. Eastern Daylight Time on Thursday, October 29, 2009. To listen to the webcast, investors can go to http://ir.bruker.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796, or [phone] outside the US and Canada. Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or [phone] outside the US and Canada, and then entering replay pass code 94562291. For more information, please visit http://ir.bruker.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties, that could cause actual future results to differ materially from those projected including, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in millions, except per share data)

Three Months Ended September 30, Nine Months Ended September 30,
2009 2008 2009 2008

Product revenue $ 230.7 $ 211.8 $ 655.8 $ 700.4
Service revenue 32.4 28.8 87.6 87.7
Other revenue 2.0 1.5 4.7 3.8
Total revenue 265.1 242.1 748.1 791.9

Cost of product revenue 127.9 114.6 364.8 382.3
Cost of service revenue 18.0 16.4 50.2 54.9
Total cost of revenue 145.9 131.0 415.0 437.2

Gross profit 119.2 111.1 333.1 354.7

Operating Expenses:
Sales and marketing 44.1 45.2 130.6 136.7
General and administrative 17.5 17.7 50.8 51.7
Research and development 31.6 33.1 91.8 100.8
Acquisition related, net - - (0.6 ) 6.2
Total operating expenses 93.2 96.0 272.6 295.4

Operating income 26.0 15.1 60.5 59.3

Interest and other income (expense), net (1.8 ) 0.8 (4.6 ) (7.8 )

Income before income tax provision and
noncontrolling interest in consolidated subsidiaries 24.2 15.9 55.9 51.5
Income tax provision 8.1 (2.0 ) 18.5 12.5

Net income 16.1 17.9 37.4 39.0
Net income (loss) attributable to noncontrolling interests (0.3 ) 0.1 (0.3 ) 0.3
Net income attributable to Bruker Corporation $ 16.4 $ 17.8 $ 37.7 $ 38.7

Net income per common share attributable to:
Bruker Corporation shareholders:
Basic $ 0.10 $ 0.11 $ 0.23 $ 0.24
Diluted $ 0.10 $ 0.11 $ 0.23 $ 0.23

Weighted average shares outstanding:
Basic 163.5 162.8 163.4 162.5
Diluted 165.0 165.9 164.7 165.6

Bruker Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)

September 30, December 31,
2009 2008

ASSETS




Current assets:
Cash, short-term investments and restricted cash $ 150.5 $ 167.7
Accounts receivable, net 151.7 171.9
Inventories 443.6 425.1
Other current assets 72.7 56.0
Total current assets 818.5 820.7

Property and equipment, net 226.4 221.3
Intangible and other assets 79.3 74.3

Total assets $ 1,124.2 $ 1,116.3

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
Short-term borrowings $ 30.9 $ 41.0
Accounts payable 45.5 43.3
Customer deposits 197.1 199.6
Other current liabilities 247.5 235.8
Total current liabilities 521.0 519.7

Long-term debt 120.4 182.8
Other long-term liabilities 109.3 101.1

Total shareholders' equity 373.5 312.7

Total liabilities and shareholders' equity $ 1,124.2 $ 1,116.3

Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the nine months ended September 30, 2009 and 2008 (unaudited)

(in millions, except per share data)

Bruker
Bruker Energy & Corporate,
Scientific Supercon Adjustments GAAP
September 30, 2009: Instruments Technologies & Eliminations Consolidated

Revenue $ 716.5 $ 36.0 $ (4.4 ) $ 748.1

Operating Income (Loss) 63.4 (4.3 ) 1.4 60.5

Net Income (Loss) 41.7 (5.0 ) 1.0 37.7

Net Income (Loss) Per Diluted Share $ 0.25 $ (0.03 ) $ 0.01 $ 0.23
Diluted Shares Outstanding 164.7 163.4 164.7 164.7


September 30, 2008:

Revenue $ 767.3 $ 32.5 $ (7.9 ) $ 791.9

Operating Income (Loss) 65.7 (6.6 ) 0.2 59.3

Net Income (Loss) 45.3 (6.8 ) 0.2 38.7

Net Income (Loss) Per Diluted Share $ 0.27 $ (0.04 ) $ 0.00 $ 0.23
Diluted Shares Outstanding 165.6 162.5 165.6 165.6

Reconciliation of Free Cash Flow of Bruker Corporation (unaudited)

(in millions)
Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008

Cash flow from operations $ 16.0 $ 0.8 $ 67.3 $ 18.9

Capital expenditures (1.8 ) (12.7 ) (8.9 ) (39.8 )

Free cash flow $ 14.2 $ (11.9 ) $ 58.4 $ (20.9 )

[MSC290]

Bruker initiated at JPMorgan.

Oct. 14, 2009

Initiated with an Overweight rating and $14 price target. Introduces 2009 EPS estimates of $0.38.

http://www.thestreet.com/story/10611269/1/barrick-analysts-upgrades-downgrades.html?cm_ven=GOOGLEFI

[wEaReLeGiOn]

A push through $11 to hit a quick $15 by


my calculations. Seems it's been on a sideways bend for a while now.

Either that or a sell off under $9 and consolidation. I wouldn't want to risk any PUTS though :)


Bruker Receives New Biotyper Accreditations

[MSC290]

Bruker Receives New Biotyper Accreditations

September 21, 2009 - GenomeWeb Daily News

NEW YORK (GenomeWeb News) – Bruker said today that its MALDI Biotyper has received accreditation for use in three new German clinical microbiology labs.

The company said that its molecular identification platform received accreditation from DACH Deutsche Akkreditierungsstelle Chemie, which is in charge of accreditation and surveillance of labs working in chemistry, biology, and medicine.

The new accreditation includes labs in Cologne, Dessau, and Karlsruhe.

http://www.genomeweb.com/proteomics/sandia-use-arrayit%E2%80%99s-nanotech-platform

[MSC290]

Family scales back secondary offering of Bruker stock

September 18, 2009 by MassDevice staff

A proposed deal by members of the founding family of the Billerica, Mass.-based maker of scientific equipment is cut by nearly two-thirds.


The Billerica, Mass.-based manufacturer of medical imaging equipment and chemical detection devices announced Friday that the mother and brother of Bruker CEO Frank Laukien intend to soon sell 12 million shares through a secondary offering of stock.

At its current price, Isolde Laukien-Kleiner would receive about $2 million in proceeds from the offering while Marc Laukien is in line for slightly more than $10 million. The company will not receive any money through the offering, which is being managed by Goldman, Sachs & Co., J.P. Morgan and Deutsche Bank Securities.

The number of shares being offered is down significantly from the nearly 20 million shares the two were planning to sell earlier this summer when Bruker filed a shelf registration with the U.S. Securities and Exchange Commission. Dirk Laukien — a Bruker vice president and Marc and Frank Laukien's half-brother — also withdrew his bid to sell a sizable portion of his Bruker holdings as part of the current offering.

Dirk Laukien had planned to sell up to 14,200 Bruker shares.

Both Marc Laukien and his mother — neither of whom are active with the company — along with several other family members have been steadily reducing their respective stakes in Bruker in recent years. The family sold a combined 22.4 million shares through a pair of secondary offerings in early 2007 and in 2004 and have also used private stock sales and a 2006 merger with Bruker Optics to cash out sizable portions of their holdings.

As part of the current deal, Frank Laukien has has agreed to a private purchase of 100,000 shares from his brother, according to a new prospectus filed late Thursday.

Bruker stock closed yesterday at $10.02 a share, up about 20 percent from the range where Bruker shares traded three months ago when the secondary offering was first proposed in June.

http://www.massdevice.com/news/family-scales-back-secondary-offering-bruker-stock

[MSC290]

Rhode Island Hospital Gets $11M NIH Grant for Cancer Core

August 31, 2009 - By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Center for Research Resources has granted Rhode Island Hospital $11 million to renew the hospital's status as a Center of Biomedical Research Excellence (COBRE) Center for Cancer Research and Development, the hospital said today.

The five-year grant will continue the COBRE CCRD programs at Rhode Island Hospital, which uses it to offer cancer researchers access and use of a proteomics core and a molecular pathology core. The proteomics core provides mass spectrometry and analysis tools and services, and the molecular pathology core provides a tissue bank for storing and cataloging human and animal tissues and a range of services.

The aim is to support researchers who seek biomarkers for use in developing early detection and diagnostic tools for cancer.

The hospital also this year received a $500,000 economic stimulus funding grant to purchase an imaging mass spectrometer for the proteomics core, Douglas Hixson, a Brown University professor who directs the hospital's Molecular Carcinogenesis Laboratory, said in a statement. The center purchased a Bruker Daltonics Ultraflex MALDI TOF/TOF with the funds.

"By allowing investigators to identify proteins differentially expressed in malignant and normal cells by directly scanning tissue sections, this exciting new technology will accelerate the identification of biomarkers by directly linking the fields of proteomics and molecular pathology," said Hixson. The new mass spectrometer is expected to "become a catalyst for collaborative interactions aimed at developing novel clinical and basic research applications," he added.

Since the hospital opened the CCRD facility in 2003 it has been involved in a range of cancer-related discoveries, Hixson said. "We've identified a new mode of transmitting signals regulating the growth and spread of cancer, a new gene that determines sensitivity to anti cancer drugs, another gene elevated by acid reflux that increases the risk of esophageal cancer and two novel tumor suppressor genes whose loss elevates the risk of stomach cancer."

http://www.genomeweb.com/proteomics/rhode-island-hospital-gets-11m-nih-grant-cancer-core

[MSC290]

Bruker Announces the Availability of the World's First 18 Tesla FTMS Magnet at IMSC 2009

Sunday, August 30, 2009 - Foxbusiness

BREMEN, Germany, Aug 30, 2009 (BUSINESS WIRE) ----At the 18th International Mass Spectrometry Conference, Bruker Daltonics today announced the availability of the world's first 18 tesla (T) magnet for FTMS. This unique, actively-shielded, refrigerated 18T magnet system with excellent homogeneity and field stability, represents the world's highest field FTMS magnet, providing unique and novel scientific capabilities that can be applied to some of today's most important, complex, and challenging protein, polymer, and small molecule analyses. The unmatched performance of FTMS at 18 tesla will significantly impact a variety of research areas including protein identification, petroleomics, metabolomics, small molecule tissue molecular imaging, and environmental sample analysis.

The new magnet system provides dramatic increases in FTMS resolution, speed, and dynamic range. Additionally, the routine observation and measurement of isotopic fine structure of molecules of interest will be facilitated and extended to larger molecules to provide another dimension of specificity for the determination of exact molecular formulae. Bruker has a long history of magnet development with many 'firsts' in high field technology. The latest of these achievements has been the June 2009 introduction of the world's first 1 GHz NMR system (23.5 tesla).

"The development of the 18T magnet for FTMS represents the next leap forward for high end FTMS," said Dr. Gerhard Roth, Managing Director of Bruker BioSpin GmbH in Karlsruhe, Germany. He continued: "The design of this new horizontal bore 18T FTMS magnet is based on Bruker's extensive design and production experience for ultra high field vertical and horizontal bore magnets for NMR, MRI, EPR and FTMS, combining the most advanced features and many of our key proprietary technologies."

Bruker Daltonics is now accepting orders for its new 18T FTMS magnet with delivery 12 months after order.

http://www.foxbusiness.com/story/markets/industries/health-care/bruker-announces-availability-worlds--tesla-ftms-magnet-imsc/

[MSC290]

Wyeth Corporation comes to the aid of UH Hilo's College of Pharmacy

Aug. 28, 2009 - University of Hawaii at Hilo

The University of Hawaii at Hilo College of Pharmacy will soon install a major instrument that will help further research at the university, thanks to a gift from the Wyeth Corporation.

The Bruker-Biospin Avance DRX 400 is a 400-megahertz nuclear magnetic resonance spectrometer (NMR) valued at a quarter million dollars, which will be used to identify the structures of unknown chemicals including potential new drugs. The equipment is being configured at the new laboratory space off Stainback Highway currently occupied by Pharmacy until the growing college has a permanent home.

“The gift of the NMR from Wyeth removes a major impediment to scientific research that must compete on a national or international scale,” said Dr. Robert P. Borris, associate dean for research at the College of Pharmacy. “Not having this kind of equipment tells federal funding agencies such as the National Science Foundation that we don’t have the facilities in which to do cutting edge research. Having the NMR at UH Hilo means we won't have to travel to Oʻahu or to the mainland to conduct our work. We're very grateful to Wyeth for helping us to establish a cutting-edge scientific base for students at UH Hilo.”

Pharmacy collaborates with faculty in chemistry, biology and biochemistry, and hopes to give ample access to anyone at UH Hilo in need of this fundamental tool for analytical chemistry, Borris said. Many of the faculty have used similar equipment, but will have to complete one or two days of training specific to this particular instrument.

The NMR uses the behavior of atoms in a strong magnetic field to help identify the structure of chemicals, both alone and in mixtures. Research that would require a NMR might ultimately result in the discovery of a new drug, which may have been synthesized in the laboratory or isolated from some natural product.

Dr. Guy T. Carter, assistant vice president of chemical technologies at Wyeth Research's Chemical & Screening Sciences, said that Wyeth tries to place retired equipment that is still functional with an academic research group that will derive the greatest benefit. The drug company, based in New York, typically chooses institutions that are in close proximity to one of their sites, such as Columbia University in Manhattan and Temple University in Philadelphia. Carter said he was able to direct the NMR to UH Hilo through personal communications with Borris.

“I find it personally gratifying that the instrument will enable UH Hilo students to have access to high quality NMR data for their studies," Carter said. “I am particularly hopeful that the NMR will be valuable in advancing research in natural products drug discovery, which we are passionate about at Wyeth.”

The gift is a signal of support from the pharmaceutical industry for the growing College of Pharmacy, said Dean John M. Pezzuto.

“We are competing for the same funding that universities everywhere need, so it's absolutely critical that we can rely on the pharmaceutical industry,” Pezzuto said. “Support from Wyeth Research is reassuring because it shows we're headed in the right direction. We are determined to continue on our planned path to improve healthcare in Hawaiʻi and the Pacific region.”

http://www.hawaii.edu/news/article.php?aId=3066

[MSC290]

Bruker to Present Major Instrument Innovations

Aug. 27, 2009 - By: Business Wire

The 18th International Mass Spectrometry Conference (IMSC) will open on August 30th, in Bremen, Germany, which is also the home of Bruker Daltonics, a leading developer of innovative life science mass spectrometry tools.

In addition to supporting IMSC as a Platinum Sponsor, and presenting more than 50 contributions in the scientific conference program, Bruker Daltonics has organized various workshops, customer days, exhibitions and company tours to present its mass spectrometry innovations to the scientific community:

* Sunday, August 30th: Bruker Daltonics International Users Conference
* Monday, August 31st and Tuesday, September 1st: Workshop Series “Achieving Highest Confidence with Complex Small Molecules Samples”, and “New Tools for Biomarker Discovery”, presented by MS experts including Don Richards (Pfizer Central Research Ltd., UK), Tony Bristow (AstraZeneca, UK), Gary Corthals (TCB, Finland), and Bernhard Kuester,(TU Munich, Germany)
* Monday, August 31st and Tuesday, September 1st: Live instrument demonstrations at our Bremen factory facility
* Wednesday, September 2nd: Bruker Daltonics factory tours running throughout the day;

At IMSC 2009, Bruker presents for the first time in Europe a number of truly innovative, high performance mass spectrometry platforms demonstrating Bruker’s “Continuing Revolution” campaign to enable the life science community for an ever increasing range of scientific investigations, as well as for advanced applied and clinical methods:

* maXis™ enabled with ETD , a technique set to revolutionize the way scientists study protein primary and secondary structures, modifications, folding and function, will be demonstrated live at IMSC 2009 to an audience of international scientists. The maXis™ is a unique high-speed Ultra-High Resolution TOF (UHR-TOF) mass spectrometer for highest performance with no-compromise for small molecule and proteomics applications. Following on from its successful introduction in 2008 and the large number of installations completed worldwide in many leading pharmaceutical and academic laboratories, the next generation maXis including high-performance ETD is now a reality. For further information: www.bdal.com/maXis

* ultrafleXtreme™ is the only fully 1 kHz MS and MS/MS enabled MALDI-TOF/TOF system available and incorporates the new smartbeam™-II laser technology and a 4 GHz digitizer. Its unmatched proteomics performance shows broad-band mass resolving power up to 40,000 and 1 ppm mass accuracy. Its unique flexibility allows LC-MALDI TOF/TOF, label-free quantitation, top-down intact protein analysis, Edmass™ protein sequencing, polymer characterization and oligonucleotide analysis. A rapid self-cleaning ion source, industry-leading imaging software and laser focal diameters down to 10 µm deliver the most powerful and complete MALDI imaging system on the market. In addition, as recently announced, the integration of the Carl Zeiss’ MIRAX Virtual Slide Scanner has enabled revolutionary advances in non-targeted molecular histology with high spatial resolution (research use only). Further information: www.bdal.com/ultrafleXtreme

* amaZon™ is the fastest ion trap available today with a 52,000 u/sec scan rate at 0.58 u mass resolution. The integration of novel, proprietary dual ion funnel technology, has increased sensitivity by an order of magnitude, and the second-generation ETD / PTR module for proteomics offers unmatched ETD sensitivity with high robustness and ease-of-use. A mass resolving power up to 20,000 in full scan mode across m/z 50-3000 makes top-down ETD experiments a reality. The fast MS data acquisition speed of 20 Hz with zero-delay polarity switching also makes amaZon the ideal instrument for all fast screening applications based on spectral libraries, including clinical toxicology and forensics. Further information: www.bdal.com/amaZon

* solariX™ is a next generation hybrid FTMS system, delivering a 10-fold improvement in sensitivity, an 8-fold gain in broadband ultra-high resolution (>1,000,000 at 7 T), and sub-ppm mass accuracy over a wide dynamic range. The complete engineering redesign makes this instrument extremely robust, uniquely powerful whilst also easy to use. SolariX is ideal for the analysis of very complex mixtures in top-down proteomics, with both ETD and ECD now as standard proteomics tools. Additional applications include petroleomics, metabolomics, and small-molecule drug and metabolite MALDI imaging on the dual ESI/MALDI source system. At the IMSC 2009, Bruker Daltonics announces the availability of the world’s first 18 tesla (T) magnet designed for FTMS applications. This unique magnet system represents the world’s highest field FTMS magnet, providing record-breaking scientific capabilities that can be applied to some of today’s most important, complex and challenging protein, polymer and small molecule analyses. For further information: www.bdal.com/solariX

Bruker Daltonics staff will be available for in-depth meetings during exhibit hours at Bruker's IMSC booth D in Hall 4.0, Monday through Friday. On Monday evening, the Hospitality Suite at the Lloyd room, CCB, is open 6 – 9 pm. A special evening event is organized for Tuesday in the famous “Bremer Ratskeller” located in the 16th century Bremen town hall. An evening reception will take place on Wednesday 5 – 7 pm at the Bruker booth in Hall 4.0. For more information on Bruker’s IMSC events, please visit www.bdal.com/imsc

http://ca.sys-con.com/node/1084798

[Bakerman_06]

I'm watching this one closely for en entry. Future looks very promising here.

[MSC290]

Bruker Corp. gets stimulated by global recovery efforts

August 26, 2009 by MassDevice staff

The Billerica, Mass.-based medical equipment maker says it's booked more than $10 million in global stimulus orders this year.

Bruker Corp.'s prediction of windfalls from economic stimulus programs around the world turned out to be true, as the company says it's booked more than $10 million in new orders stemming from stimulus cash in Japan, Europe and the U.S.

The Billerica, Mass.-based medical equipment manufacturer said last month that government stimulus spending could eventually pump an extra $200 million — or possibly more — of new revenue into its coffers.

And according to a filing with the Securities and Exchange Commission, the money is already starting to trickle in.

As part of its presentation at an institutional investors conference in Zurich, Switzerland, company executives revealed that Bruker received "stimulus orders" in Japan, Europe and America, including five orders from Japan for more than $3 million (and not including $12 million worth of previously booked Japanese orders).

"Additional significant NMR, mRI, EPR, X-ray crystallography, high-end mass spectrometry and other systems orders are expected from global stimulus funding in Q3 and Q4 of 2009, and into 2010," according to the presentation.

Bruker posted sales of $252.5 million during the three months ended June 30, down nearly 19 percent compared with $311.5 million during the same period last year. Net income for the period plunged more than 40 percent to $12.9 million, compared with $21.7 million in the year-ago quarter.

http://www.massdevice.com/news/bruker-corp-gets-stimulated-global-recovery-efforts

[OneRichSOB]

hey all - new to brkr here. About to buy in tomorrow. Wish me luck!

[MSC290]

Bruker CEO ups stake

August 4, 2009 by MassDevice staff

Billerica, Mass.-based imaging equipment maker CEO Frank Laukien boosts his stake in the company to 23.4 percent.

Laukien family members may sell some of their Bruker Corp. stock from time to time, but it doesn't seem to stay away for long.

Less than two months after his mother and two siblings disclosed plans to unload a large chunk of their stake, CEO Frank Laukien bought up another 150,000 shares in the Billerica, Mass.-based medical imaging equipment manufacturer from outside investors, according to filings with the federal Securities and Exchange Commission.

Laukien made the purchases — $1.51 million worth of stock at an average price of $10.03 — via a series of small transactions July 31 and August 3. The latest buying spree follows a familiar Laukien pattern established in recent years: They sell and he buys, although not necessarily from each other.

Since last November, Frank Laukien has spent close to $7.5 million of his own funds to acquire an additional 1.6 million shares. He now owns 38,449,445 shares, or roughly 23.4 percent of the company.

Other Laukien family members control another 45 percent of Bruker stock. That combined stake, however, would dip to roughly 22.5 percent if the company moves ahead with a proposed secondary offering that includes the sale of 35 million shares now held by Isolde Laukien-Kleiner and Dirk and Marc Laukien.

Frank Laukien's recent purchases came through open-market deals, rather than the exercising of options or other stock awards. He was also a significant player in overall trading of Bruker stock during the past few days, accounting for 14 percent of total volume on Friday and Monday.

One reason might be Bruker Corp.'s rather stingy ways with option grants. Frank Laukien holds vested options to buy a total of 175,000 shares — with only 75,000 of those options priced below Monday's closing price of $10.09, according to company proxy statements.

http://www.massdevice.com/news/bruker-ceo-ups-stake

[wEaReLeGiOn]

Bruker Announces New Mass Spectrometry Joint Venture in India

Date : 07/31/2009 @ 7:00AM
Source : Business Wire
Stock : Bruker Daltonics (BRKR)
Quote : 9.61 0.6 (6.66%)

http://ih.advfn.com/p.php?pid=nmona&cb=1249038276&article=38855302&symbol=N^BRKR



Bruker Daltonics announced today the establishment of the Bruker LabMate Private Limited company, a life-science mass spectrometry joint venture between Bruker Daltonics and LabMate Asia, with customer support and technical expertise hubs in Bangalore, Chennai, Delhi, Kolkata and Mumbai. Building on a successful partnership built over 7 years with Bruker’s Indian mass spectrometry distributor LabMate Asia Pvt., the new company marks a seamless transition of established business and customer care teams to a majority-owned Bruker company.

At the core of the establishment of this Bruker LabMate joint venture is a firm commitment to customer service, training and support made fully accessible to Bruker Daltonics’ top-tier academic and pharmaceutical industry clients by a geographically distributed technical staffing structure. “We already set the customer care standards in India by which other research mass spectrometry suppliers are judged, and we see it as directly responsible for our success,” commented Dr. Ian Sanders, Executive Vice President of Bruker Daltonics. He continued: “Adding to our training and applications strength in India is the logical next move to ensure our customers succeed as quickly as possible in this very exciting and dynamic scientific community.”

“We are excited to enter this next phase of growth for our achievements as mass spectrometry pioneers in India,” commented Mr. S. Viswanathan ([e-mail]), an Executive Director of Bruker LabMate, who together with Executive Director Mr. S. Kumaraguruparan (‘Kumar’ / [e-mail] ), bring over 40 years of combined experience in scientific instrumentation supply to the management of Bruker LabMate. Speaking at the inauguration of the Bruker Indian Institute of Science Mass Spectrometry Facility in Bangalore on 23rd July 2009, Mr. Kumar concluded: “This is great news for our customers, adding the full commitment of Bruker Daltonics behind our very long-standing and close relationships with many key Indian scientists.”

ABOUT BRUKER DALTONICS

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com, www.bdal.in and www.bruker.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6019571〈=en

[wEaReLeGiOn]

Bruker Corporation Reports Second Quarter

2009 Financial Results

http://ih.advfn.com/p.php?pid=nmona&cb=1248880657&
article=38816580&symbol=N^BRKR

8K http://ih.advfn.com/p.php?pid=nmona&cb=1248880684&article=38816797&symbol=N^BRKR

Bruker Corporation (NASDAQ: BRKR) today reported financial results for the second quarter ended June 30, 2009.

Second Quarter 2009 Highlights

* Revenue $252.5 million
* GAAP Net Income $12.9 million
* GAAP EPS $0.08 per diluted share
* Free cash flow $32.8 million
* After acquisition of ACCEL RI business on April 1, 2009, Bruker established new Energy & Supercon Technologies segment
* Bruker’s Scientific Instruments segment launched numerous innovative products with compelling performance and capabilities: Avance III 1,000 MHz NMR, ultrafleXtreme TOF/TOF, amaZon ion trap, solariX FTMS and 263 GHz EPR

Financial Results

In the second quarter of 2009, revenue was $252.5 million, a decrease of 18.9% compared to revenue of $311.5 million in the second quarter of 2008. Excluding the effect of foreign currency translation, second quarter 2009 revenue decreased 11.1% year-over-year. Sequentially, revenue increased 9.5% over the first quarter of 2009. GAAP net income for the second quarter of 2009 was $12.9 million, or $0.08 per diluted share, compared to GAAP net income of $21.7 million, or $0.13 per diluted share, in the second quarter of 2008. Included in GAAP EPS in the second quarter of 2009 was non-cash stock-based compensation expense of ($0.01) per diluted share.

For the six months ended June 30, 2009, revenue was $483.0 million, a decrease of 12.2%, compared to revenue of $549.8 million in the first half of 2008. Excluding the effect of foreign currency translation, revenue for the six months ended June 30, 2009 decreased by 4.4% year-over-year. GAAP net income for the six months ended June 30, 2009 was $21.3 million, or $0.13 per diluted share, compared to GAAP net income of $20.9 million, or $0.13 per diluted share, during the six months ended June 30, 2008. Included in GAAP EPS for the six months ended June 30, 2009 was non-cash stock-based compensation expense of ($0.02) per diluted share.

Free cash flow for the second quarter of 2009 was $32.8 million. During the second quarter of 2009, Bruker repaid $34.1 million of debt, and ended the quarter with cash and cash equivalents of $154.3 million, and net debt of $16.4 million.

Comment and Outlook

Frank Laukien, Bruker’s President and CEO, commented: “Considering the challenging economic conditions in the industrial markets, we are pleased with our performance in the second quarter and first half of 2009. In the second quarter of 2009, we experienced solid top line growth sequentially, while the year-over-year revenue comparison was expected to be more difficult due to our revenue spike in the second quarter of 2008. On the bottom line, our cost-cutting measures, the strength of our new product lines and the impact of our business initiatives had a positive impact on our second quarter 2009 results, and contributed to our 54% sequential growth in net income.”

Dr. Laukien continued: “During the second quarter we continued to strengthen our product portfolio and launched several compelling mass spectrometry products at ASMS 2009, while also introducing the world’s first 1 Gigahertz NMR system. Our life-science mass spectrometry business delivered strong double-digit revenue growth and significant margin improvements in the second quarter of 2009. Moreover, after the acquisition of the ACCEL RI business by our Bruker Advanced Supercon business, we have established the new Bruker Energy & Supercon Technologies division, which is emerging as a global leader in superconductors and supercon devices, as well as in advanced technologies for energy research and next-generation grid infrastructure.”

Bruker’s Chief Financial Officer, Bill Knight, added: “While the downturn in the global economy continues to be challenging to navigate, we are relatively well positioned to handle these challenges with our strong technology and IP base, our high-performance product portfolio and our broad international diversification. Moreover, we derive nearly 70% of our revenue from universities and medical schools, as well as from other non-profit and government customers, who tend to be less sensitive to economic conditions. Going forward, we expect the global government stimulus programs to have a positive impact on our high-end life-science and research systems business, as well as on our new Bruker Energy & Supercon Technologies division, starting in the second half of 2009, accelerating in 2010, and continuing into 2011.”

Segment Information

After Bruker’s acquisition of the ACCEL Research Instruments business on April 1, 2009, starting with the second quarter of 2009, Bruker has established two new reportable segments:

1) The Bruker Scientific Instruments (BSI) segment consists of the four divisions Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics.

2) The new Bruker Energy & Supercon Technologies (BEST) segment which combines the acquired ACCEL RI business, and the superconductor and supercon devices business that was previously called Bruker Advanced Supercon, Inc.

Revenue in the BSI segment for the six months ended June 30, 2009 was $464.9 million, compared to BSI revenue of $533.5 million for the six months ended June 30, 2008. Excluding the effects of foreign currency translation, first half 2009 BSI revenue decreased by 5.4% year-over-year. BSI net income for the six months ended June 30, 2009 was $23.5 million, compared to $24.7 million for the six months ended June 30, 2008. BSI earnings per diluted share for the six months ended June 30, 2009 were $0.14, compared to $0.15 for the six months ended June 30, 2008.

Revenue in the BEST segment for the six months ended June 30, 2009 was $21.8 million, compared to BEST revenue of $22.4 million for the six months ended June 30, 2008. Excluding the effects of foreign currency translation, first half 2009 BEST revenue increased by 12.3% year-over-year. BEST net loss for the six months ended June 30, 2009 was ($3.4) million, compared to a net loss of ($4.0) million for the six months ended June 30, 2008. BEST loss per diluted share for the six months ended June 30, 2009 was ($0.02), compared to ($0.02) for the six months ended June 30, 2008.

Following at the end of this press release is a non-GAAP table reconciling the results of our reportable segments to the consolidated results of Bruker Corporation.

USE OF NON-GAAP FINANCIAL MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the measures of non-GAAP revenue, non-GAAP operating income, non-GAAP net income and non-GAAP EPS, by reportable segment. We believe that such non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included in this press release are not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying table. Specifically:

* Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the six months ended June 30, 2009 and 2008

EARNINGS CONFERENCE CALL

Bruker Corporation will host an operator-assisted earnings conference call at 9:00 a.m. Eastern Daylight Time on Wednesday, July 29, 2009. To listen to the webcast, investors can go to http://ir.bruker.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796, or [phone] outside the US and Canada. Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or [phone] outside the US and Canada, and then entering replay pass code 15184127. For more information, please visit http://ir.bruker.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in millions, except per share data)


Three Months Ended June 30, Six Months Ended June 30,
2009 2008 2009 2008
Product revenue $ 222.9 $ 280.3 $ 425.1 $ 488.6
Service revenue 28.3 30.2 55.2 58.9
Other revenue 1.3 1.0 2.7 2.3
Total revenue 252.5 311.5 483.0 549.8

Cost of product revenue 125.2 162.5 236.9 267.7
Cost of service revenue 16.1 19.4 32.2 38.5
Total cost of revenue 141.3 181.9 269.1 306.2

Gross profit 111.2 129.6 213.9 243.6

Operating Expenses:
Sales and marketing 43.9 47.1 86.5 91.5
General and administrative 17.0 17.2 33.3 34.0
Research and development 31.1 36.5 60.2 67.7
Acquisition related, net (1.0 ) 0.4 (0.6 ) 6.2
Total operating expenses 91.0 101.2 179.4 199.4

Operating income 20.2 28.4 34.5 44.2

Interest and other income (expense), net (2.9 ) 3.6 (2.8 ) (8.6 )

Income before income tax provision and
noncontrolling interest in consolidated subsidiaries 17.3 32.0 31.7 35.6
Income tax provision 4.6 10.3 10.4 14.5

Net income 12.7 21.7 21.3 21.1
Net income (loss) attributable to noncontrolling interests (0.2 ) - - 0.2
Net income attributable to Bruker Corporation $ 12.9 $ 21.7 $ 21.3 $ 20.9

Net income per common share attributable to:
Bruker Corporation shareholders:
Basic and diluted $ 0.08 $ 0.13 $ 0.13 $ 0.13

Weighted average shares outstanding:
Basic 163.3 162.4 163.3 162.4
Diluted 164.7 165.5 164.5 165.3

Bruker Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)

June 30, December 31,
2009 2008
ASSETS




Current assets:
Cash, short-term investments and restricted cash $ 154.3 $ 167.7
Accounts receivable, net 132.9 171.9
Inventories 436.4 425.1
Other current assets 65.6 56.0
Total current assets 789.2 820.7

Property and equipment, net 221.3 221.3
Intangible and other assets 77.0 74.3

Total assets $ 1,087.5 $ 1,116.3

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
Short-term borrowings $ 43.1 $ 41.0
Accounts payable 40.8 43.3
Customer deposits 202.1 199.6
Other current liabilities 233.2 235.8
Total current liabilities 519.2 519.7

Long-term debt 127.6 182.8
Other long-term liabilities 104.2 101.1

Total shareholders' equity 336.5 312.7

Total liabilities and shareholders' equity $ 1,087.5 $ 1,116.3

Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the six months ended June 30, 2009 and 2008 (unaudited)

(in millions, except per share data)

Bruker
Bruker Energy & Corporate,
Scientific Supercon Adjustments
June 30, 2009: Instruments Technologies & Eliminations Consolidated

Revenue

$


464.9
$ 21.8 $ (3.7 ) $ 483.0

Operating Income 36.5 (3.1 ) 1.1 34.5

Net Income 23.5 (3.4 ) 1.2 21.3

Net Income Per Diluted Share $ 0.14 $ (0.02 ) $ 0.01 $ 0.13
Dulited Shares Outstanding 164.5 163.3 164.5 164.5


June 30, 2008:

Revenue $ 533.5 $ 22.4 $ (6.1 ) $ 549.8

Operating Income 47.7 (3.7 ) 0.2 44.2

Net Income 24.7 (4.0 ) 0.2 20.9

Net Income Per Diluted Share $ 0.15 $ (0.02 ) $ 0.00 $ 0.13
Dulited Shares Outstanding 165.3 162.4 165.3 165.3

[wEaReLeGiOn]

So far he's made a tidy sum, were he to sell :)



Bruker CEO buys $10M in company stock

[MSC290]

Bruker CEO buys $10M in company stock

Monday, March 16, 2009 - Boston Business Journal - by Craig M. Douglas

Frank Laukien, the chairman and CEO of life-sciences equipment maker Bruker Corp., has padded his ownership stake in the company to roughly 23 percent, acquiring $10.7 million in Bruker stock between March 5 and March 10.

Laukien, 48, has been CEO of Billerica, Mass.-based Bruker since 1991. His total stake in the company, some 38.2 million shares, is worth just shy of $200 million, based on Monday’s opening trading price of $5.09 a share.

Bruker (Nasdaq: BRKR) makes and distributes equipment and technologies used by drug makers and other product developers in the life sciences sector. The company booked $1.1 in revenue and $64.9 million in net income last year.


http://boston.bizjournals.com/boston/stories/2009/03/16/daily1.html

[MSC290]

Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 125,000 Shares

Mar. 09, 2009 - gurufocus

CEO/President, 10% Owner of Bruker BioSciences Corp. (BRKR) Frank H Laukien buys 125,000 shares of BRKR on 03/09/2009 at an average price of $4.2 a share.

As of February 26 2008 the renamed BRUKER CORPORATION has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group Bruker Corporation now operates in two segments the life science and analytical (LSA) systems segment and the international advanced superconductor (IAS) segment. Bruker BioSciences Corp. has a market cap of $626.73 million; its shares were traded at around $3.82 with a P/E ratio of 8.13 and P/S ratio of 0.57.

http://www.gurufocus.com/news.php?id=50781

[MSC290]

Bruker Announces Opening of Expanded, State-of-the-Art Applications and Demonstration Facility in Yokohama, Japan

2-24-2009

Bruker Corporation (NASDAQ: BRKR) announced the opening of its expanded, state-of-the-art multi-technology applications and demonstration laboratory, which is co-located with Bruker’s R&D and manufacturing facility for X-ray analysis systems in Yokohama.

Yesterday, more than 150 customers, collaborators and business partners witnessed the ribbon-cutting ceremony for Bruker’s expanded 3,000 square-meter Yokohama facility, and then joined Bruker’s management for a seminar on the latest scientific instruments and analytical solutions.

The new Yokohama facility is the single largest combined Bruker applications laboratory in the world, showcasing a wide selection of novel life science, materials research and industrial systems including NMR, research MRI, EPR, MALDI-TOF/TOF, ESI-ITMS and ESI-Qq-TOF mass spectrometry, X-ray diffraction and crystallography, X-ray fluorescence (XRF), EDS accessories for SEM, FT-IR and thermal analysis systems.

Mr. Sadao Ueki, President of Bruker AXS K.K. and Representative Director of various Bruker subsidiaries in Japan, commented: “Our expanded applications facility provides the opportunity for scientists from Japan and Asia to investigate a wide range of applications on our innovative systems, together with obtaining training, demonstrations and advice from Bruker’s experienced Yokohama-based team of application scientists, plus visiting specialists from our worldwide factories.”

Dr. Frank Laukien, Bruker President and CEO, added: “We have recently expanded the range of products that we offer in Japan, for example now including our TRACER handheld XRF systems, our new S8 TIGER high-end WDXRF system, as well as our new maXis ultra-high performance TOF mass spectrometer. As we have almost 10 billion Yen in revenue and close to 150 employees in Japan, we have decided to expand and combine most of our operations in Japan in Yokohama, with additional sales offices in Osaka and Tokyo. We are very pleased with our modern, new applications laboratory and invite our customers in Japan to take advantage of our advanced capabilities here.”

http://www.ad-hoc-news.de/bruker-announces-opening-of-expanded-state-of-the-art--/de/Unternehmensnachrichten/20068834

[wEaReLeGiOn]

A picture is worth a thousand words-

[MSC290]

Bruker stock jumps after contract announcement

Thursday, January 15, 2009 - Boston Business Journal

Bruker’s stock spikes on spectrometer order Billerica-based Bruker Daltonics, a subsidiary of Bruker Corp., announced today the sale of 51 mass spectrometers to the National Japanese Police Agency.

The deal is worth $12 million. The announcement caused the stock to rise over 36 percent to $4.57 in late afternoon trading Wednesday — up from the previous-day’s close of $3.35. The deal calls for the spectrometers to be installed in all of the Japanese Policy Agency’s forensic labs and will be delivered in March.

A mass spectrometer separates and identifies certain molecules from compounds. For instance, the spectrometer can identify dangerous substances like melamine in food. Bruker (Nasdaq: BRKR) CEO Frank Laukien recently announced he would take a 25 percent salary cut, from $424,000 in 2008 to $318,750 this year.

Bruker's revenue during the first nine months in 2008 was $242 million, up from $214 million in the same period in 2007. Net income for the three quarters ended Sept. 30 was $17.8 million

The Billerica-company’s stock price fell 70 percent in 2008, but is up roughly 12 percent this year.

http://www.bizjournals.com/boston/stories/2009/01/12/daily44.html

[MSC290]

Bruker BioSciences Corp. (BRKR): CEO, President, Frank H Laukien Bought 250,000 Shares

CEO, President, Director, 10% Owner of Bruker BioSciences Corp. (BRKR) Frank H Laukien bought 250,000 shares during the past week at an average price of $5.31. Bruker BioSciences Corp. has a market cap of $864.72 million; its shares were traded at around $5.31 with a P/E ratio of 49.17 and P/S ratio of 1.37.

Bruker recently announced that its profits fall by 33%. This drop was caused by increased operating costs, the company said. Revenue was up slightly, but total operating expenses were on the rise.

Director, 10% Owner Joerg C Laukien bought 50,000 shares of BRKR stock on 11/05/2008 at the average price of $5.5; the price of the stock has decreased by 3.45% since.

http://www.gurufocus.com/news.php?id=38104

[MSC290]

Bruker Biospin 950 mention


Campus Celebrates Historic Milestone

20 October 2008 - International Business Times

KANNAPOLIS, N.C., Oct. 20 /PRNewswire/ -- Academia, science, industry and government leaders gathered in Kannapolis, Monday, October 20th at 10 AM at the Dedication and Open House celebration for the David H. Murdock Core Laboratory Building, the UNC Nutrition Research Building and the NC State Fruit and Vegetable Science Institute Building. The UNC Nutrition Research Building is home to NC A&T University, NC Central University, UNC Chapel Hill and UNC Greensboro. NC State University, Appalachian State University, and Dole Food Company will occupy the NC State Fruit and Vegetable Science Institute Building at the NC Research Campus. UNC Charlotte will have tenure track faculty members located in the UNC Nutrition Building and the NC State Fruit and Vegetable Science Institute Building, and will also have a presence in the 311,000 square foot David H. Murdock Core Laboratory Building. "This campus fulfills my lifelong dream of being able to change the world's thoughts on nutrition and find ways to cure many of the dreadful diseases that have affected all of us and our families. It excites me to think of the groundbreaking research that will occur as a result of having these world class universities and companies here working together all in one place,"stated David Murdock.
Erskine B. Bowles, President of the UNC System along with Dr. Steven Leath, Vice President of Research for the UNC System and Dr. Victor J. Dzau,Chancellor for Health Affairs, Duke University and President and CEO, Duke University Health System spoke at the event. Dr. Stanley F. Battle,Chancellor, NC A&T University, Dr. Linda P. Brady, Chancellor, University of North Carolina Greensboro, Dr. Philip L. Dubois, Chancellor, University of North Carolina Charlotte, Dr. Charlie Nelms, Chancellor, North Carolina Central University, Dr. James L. Oblinger, Chancellor, North Carolina State University, Dr. Kenneth E. Peacock, Chancellor, Appalachian State University,and Vice Chancellor Dr. Tony G. Waldrop of the University of North Carolina Chapel Hill were on hand to represent each of their respective universities on the dais. In addition, representatives from a number of other universities within the UNC System were in attendance. President Erskine Bowles said, "I'm immensely proud that researchers and graduate students from seven UNC campuses are actively involved at the NC Research Campus, but what really energizes and excites me is all the cutting-edge research and life-altering discoveries that will happen within these world-class laboratories and facilities. With education, government, and the private sector working together in partnership,this Research Campus has enormous potential to create new jobs and spur economic development in our state."

Special guests included US Senator Elizabeth H. Dole, US Senator Richard M. Burr, US Congressman Robin C. Hayes, US Congressman J. Howard Coble, US Congressman Mel Watt, Lieutenant Governor Beverly E. Perdue, NC Secretary of State Elaine Marshall, along with former Governors James B. Hunt, Jr. and James G. Martin. Senator Marc Basnight, President Pro Tempore, NC Senate, and Speaker Joe Hackney, Speaker of the NC House of Representatives, along with NC Senator Fletcher L. Hartsell, Jr., led the delegation of area representatives from the NC Senate and NC House of Representatives to the dais. "This campus is a shining example of the future and vision of the state of North Carolina,"remarked Senator Fletcher Hartsell. "I am reminded of Thomas Jefferson's quote, 'I like the dreams of the future better than the history of the past.'I can only imagine what great discovery and promise lies ahead because of the collaboration on this campus." Senator Dole, Senator Burr, Congressman Hayes,Senator Basnight, and Senator Hartsell return to the campus after having been present for the announcement of the NC Research Campus on September 25, 2005and subsequent events in the development of the campus. The NC Research Campus is poised to generate 30,000 jobs for the state of North Carolina in the next12 - 15 years. "The North Carolina Research Campus will strengthen our state's standing as a national biotech leader, it will create new jobs, and its scientific innovations will improve the health and well-being of people around the world," said Lt. Governor Bev Perdue. "Biotechnology is the next frontier of health science and as new discoveries are made, North Carolina will lead the way." The Mayor of Kannapolis, Robert S. Misenheimer, along with many other dignitaries from surrounding counties and cities participated in the dedication ceremony and tours of the buildings. Dr. Carol Spalding, recently named as President of Rowan Cabarrus Community College, was seated on the dais representing the community college for the celebration.

In addition to academic institutions, top officials from a number of companies who will have a strong presence on the NC Research Campus were on hand for the event. Those companies include Carolinas Healthcare System, Cabarrus Health Alliance, Dole Food Company, LabCorp, Pharmaceutical Product Development, Sensory Spectrum, Anatomics, Red Hat, Lovelace Respiratory Research Institute and the Charlotte Research Institute. Researchers from academia, science and industry will be focused on studying health, nutrition,and agriculture. Primary areas of concentration are cancer, cardiovascular disease, diabetes, obesity, brain development, liver disease and osteoarthritis.

The ceremony was held at the main entrance on Research Campus Drive near the front steps into the David H. Murdock Core Laboratory Building. The public was invited to park in the new parking deck adjacent to the site of the event.

The 350 acre campus is a public-private venture created to foster collaboration and further knowledge in biotechnology, nutrition, agriculture,and health. The David H. Murdock Research Institute, located within the David H. Murdock Core Laboratory, will house the most state-of-the art scientific equipment in the areas of genomics, proteomics, metabolomics, animal and plant imaging, microscopy, and structural chemistry. In preparation for the opening of the campus, the DHMRI has purchased the first phase of equipment for the various core laboratories, including the Bruker Biospin 950 MHz NMR. In addition to the DHMRI initiative, David H. Murdock has invested $35 million ina longitudinal population-based research initiative led by Duke University to examine the behavioral and genetic differences in people that lead to the development of disease. The project, entitled the M.U.R.D.O.C.K Study, is an acronym for Measurement to Understand the Reclassification of Disease in Cabarrus/Kannapolis. It will be conducted on site by Duke University scientists and their collaborators and will span over a number of years."This beautiful, one-of-a-kind Core Laboratory is the heart of the Campus, and I believe it represents an unprecedented opportunity for scientists here to perform breakthrough research that can eventually transform the way we think about and practice medicine," said Dr. Victor Dzau.

Mr. Murdock's vision for the campus is for the NC Research Campus to be the epicenter of health, wellness and disease research in the world. The presence of vast scientific and human resources combined in a unique collaborative environment on the campus will increase the flow of information from the academic laboratory to industry, resulting in an improvement in the quality of life for people here and around the world. "The possible collaboration of the different entities at the NC Research Campus is endless and will be the start of a whole new era of collaborative research and innovation to benefit mankind," stated David Murdock. "And that's good news for a world needing to hear good news."

http://www.ibtimes.com/prnews/20081020/nc-research-campus.htm

[mackenzian]

OT: msc290...
received your pm but am not a paying customer so cannot reply.

On another note: Looks like a nice chart here...I might have to do some DD on Burker BioSciences. Interesting what one finds here on Ihub MBs.

mack

[e-mail]

[wEaReLeGiOn]

Sweet chart here MSC :)

[MSC290]

Bruker Corporation (BRKR) more shares bought by Blackrock Advisors Llc

LONG BEACH - Blackrock Advisors Llc added additional 1,130,850 (104.91 %) shares of Bruker Corporation (BRKR), bringing their current holdings to 2,208,700 shares as shown by filings made public on 2008-08-07.

http://www.mffais.com/newsarticles/2008-08-07/2361912-208070.html

Claymore Advisors Llc added additional 18,670 (66678.57 %) shares of Bruker Corporation (BRKR), bringing their current holdings to 18,698 shares as shown by filings made public on 2008-08-07.

http://www.mffais.com/newsarticles/2008-08-07/2361912-124720.html

[MSC290]

Bruker Corporation (BRKR) more shares bought by Century Capital Management Llc

LONG BEACH - Century Capital Management Llc added additional 311,669 (12.99 %) shares of Bruker Corporation (BRKR), bringing their current holdings to 2,709,519 shares as shown by filings made public on 2008-08-06.

The stock is currently owned by 203 funds/institutions.

http://www.mffais.com/newsarticles/2008-08-06/2361912-125909.html

[Greencake]

BRKR still treating you all right there buddy?

ttys and GL,

JT

[MSC290]

Spectrometer installation under way at Core Lab

Tuesday, August 5, 2008 By Ben McNeely - independenttribune.com

KANNAPOLIS - The room is ready and the crane is in place.

Workers began installation of four nuclear magnetic resonance spectrometers Monday at the Core Research Laboratory. The supermagnets will be the centerpiece of the Core Lab’s state-of-the-art equipment cache at the North Carolina Research Campus.

Castle & Cooke president Lynne Scott Safrit said the installation process will probably take about three to four weeks.

“It’s really exciting here,” she said. “This month is when you really start to see the scientific equipment start to move in.”

The NMRs - powerful supermagnets that allow researchers to study component parts of molecules - are just some of the major pieces of scientific equipment to be installed in the Core Lab. Bruker Biospin, a German scientific equipment company, is manufacturing the NMRs for the research campus.

Outside the Core Lab, workers set up a crane that will lift the 950-mHz into the air and down into the Core Lab’s basement. Drivers on Main Street slowed down to see what was going on.

Inside the basement laboratory, four NMRs will sit - two of them, the 950 mHz and the 700 mHz, on a specially designed floating floor, Safrit said, to keep them stable. Another NMR lab, on the fourth floor, will feature a 400 mHz NMR. Two technicians from Bruker will spend about a year in Kannapolis, calibrating the NMRs to make sure they are working within optimal working parameters.

In the basement, workers are completing work on the vivarium, a large containment area for keeping live plant and animal specimens used in research, Safrit said.

Dole Food Company owner David Murdock left Kannapolis on Friday after a visit with TV’s Martha Stewart. Safrit said Murdock was “very excited” about the progress made at the research campus.

“He hadn’t seen it since late May, when he was last here,” Safrit said.

Since May, new streetscapes and landscaping have been installed on the campus. As the Core Lab nears completion, the UNC and N.C. State buildings are also close to opening.

Safrit said Castle & Cooke is eyeing a date in late September or early October for a grand opening celebration for the Core Lab.

http://www.independenttribune.com/servlet/Satellite?pagename=CIT%2FMGArticle%2FCIT_BasicArticle&c=MGArticle&cid=1173356017770&path=!news

[MSC290]

Bruker Corporation (BRKR) newly added by Pharmaceuticals Portfolio

July 31, 2008 By: BRANDON MASON Approving Editor: BETTY YOUNG

LONG BEACH (Mffais.com) - Pharmaceuticals Portfolio (Fidelity Select Portfolios) added the Bruker Corporation (BRKR) company to their portfolio, by buying 17,300 shares as shown by filings made public on 2008-07-30.

The stock is currently owned by 205 funds/institutions.

http://www.mffais.com/newsarticles/2008-07-30/2361912-95274.html

[MSC290]

A Contact Lens for Lasers

A tiny lens integrated into semiconductor lasers promises better portable chemical sensors.

Monday, July 28, 2008 By Katherine Bourzac - Technology Review

Researchers at Harvard University and Hamamatsu Photonics have created a highly directional semiconductor laser that should--by averting light loss with a nano-patterned metal coating akin to a contact lens--enable highly sensitive portable chemical sensors and cheaper, more efficient optical communications.

The new technology consists of a metal grating patterned on the light-emitting face of the laser. The grating decreases the divergence of the laser light by a factor of 25, eliminating the need for bulky, expensive mirrors and lenses. "It's a hell of a lot smaller" than traditional optics, says Alan Willner, who leads the Optical Communications Laboratory at the University of Southern California. "You can integrate it right on the [laser] structure," says Willner, who was not involved in the research. What's more, by adjusting the design of the metal grating, the researchers say, they can tune it to work with any kind of semiconductor laser.

Semiconductor lasers are widely used in everything from DVD players to telecommunication networks. In chemical-sensing systems, they're used to illuminate gaseous compounds whose identity and concentration can be determined by looking at the spectrum of light they emit.

As light travels out of a laser, it spreads out in a cone shape. Even with meticulously aligned lenses and mirrors, some light is wasted. These additional optics are expensive and make laser systems bulky. The Harvard researchers, led by physicist Federico Capasso, attacked the problem by depositing a layer of metal a few hundred nanometers thick on the facet of a laser, then etching it with slits and an aperture. Such metal gratings can be created using conventional fabrication techniques.

A large portion of light coming out the aperture bends 90 degrees and then propagates down the metal grating in a form of energy called surface plasmons. The grooves in the metal grating then scatter this energy into a narrow beam of light.

The researchers demonstrated the technique on a quantum-cascade laser, a type of laser developed by Capasso at Bell Labs in 1994. Quantum-cascade lasers can emit light over a broad spectrum--from the infrared to the visible. Light from the type of quantum-cascade laser used to test the gratings normally diverges at angles ranging from 40 to 80 degrees. In an article published online this week in the journal Nature Photonics, the Harvard and Hamamatsu researchers report that light from their laser diverges by only 2.5 degrees without significantly reducing the laser's power output.

This difference could make it possible to integrate quantum-cascade lasers into portable chemical sensors. Systems incorporating such lasers can detect a wide range of compounds with great sensitivity. However, due to divergence, these lasers are currently impractical for chemical sensors. The lasers aren't powerful enough over long distances to perform sensitive measurements. Bulky lenses improve their sensitivity but make it difficult to transport them.

Bruker Optics, of Billerica, MA, is collaborating with Capasso to develop chemical sensors incorporating compact lasers for the battlefield. "Quantum-cascade lasers would be immensely useful to monitor the output from power plants and automobiles and to detect chemical agents," says Tom Tague, chief scientist at Bruker Optics.

"This is very exciting work," says Claire Gmachl, a professor of electrical engineering at Princeton University. "This is an important advance for quantum-cascade lasers, but also offers new prospects for other types of semiconductor lasers." The metal gratings "should be useful over a plethora of applications, for any optical signal processing," says Willner.

http://www.technologyreview.com/Infotech/21135/page1/

[MSC290]

Bruker Patent

July 25, 2008 - Cell-Based Assay News

Bruker Biospin has been awarded US Patent 7,402,437, “Method and device for analyzing the intracellular chemical state of living cells by nuclear magnetic resonance.”

The inventors listed on the patent are Benjamin Gonzalez, Martial Piotto, and J. Gaspard Huber.

As described in its abstract, the patent describes a method for analyzing the intracellular chemical state of living cells by nuclear magnetic resonance. The method comprises preparing the cell sample and performing an NMR analysis on the sample.

Both steps are carried out at a very low temperature to freeze the biochemical state of the living cells, in order to obtain specific and accurate reproducible measurements of cellular functioning.

The invention also describes the device coupled to the NMR spectrometer for implementing the analysis.

http://www.cba-news.com/issues/5_30/patentwatch/148428-1.html

[kraigger23]

About time for next leg UP

[MSC290]

Bruker Daltonics announces the maXis(TM), redefining high speed, ultra high resolution mass spectrometry

Bremen Germany -- Bruker Daltonics' new maXis(TM), an Electrospray Ultra-High Resolution tandem Time of Flight (UHR-Qq-TOF) mass spectrometer demonstrates Bruker's leadership in cutting-edge mass spectrometers.

It is designed to meet future requirements in applications including small molecule identification, metabolomics, quantitative proteomics, as well as biomarker discovery and validation.

The maXis is unique in offering simultaneous no-compromise ultra-high resolution of 40,000 - 60,000 FWHM over a broad mass range, MS and MS/MS mass accuracy typically between 600 and 800 ppb, and all at speeds of up to 20 full spectra per second.

With its unprecedented performance combination, the maXis offers:

-- 20 Hz full spectra acquisition at ultra-high mass resolution
for high-speed liquid chromatography

-- 40,000 - 60,000 resolution in both MS and MS/MS mode over a
broad mass range

-- excellent high m/z mass range

-- novel IonCooler(TM) technology delivers excellent MS/MS
sensitivity over a broad m/z range

-- high dynamic range of 5 orders of magnitude for trace
detection in complex mixtures

-- sub-ppm mass accuracy in both MS and MS/MS mode for high
confidence IDs

-- uncompromised MS sensitivity for discovery applications

-- SmartFormula(TM) 3D unambiguous determination of molecular sum
formulae for molecules up to 1 kDalton;

"Now ultra-high resolution mass spectrometry over broad mass ranges is finally compatible with ultra performance liquid chromatography," explained Bruker Daltonics Executive Vice President Dr. Ian Sanders.

"Our new maXis indeed represents a major step forward in tandem mass spectrometry, offering a no-compromise solution for exceptional accurate mass, ultra-high resolution over a broad mass range and high sensitivity MS and MS/MS analysis at a speed able to take full advantage of modern, fast liquid chromatography or fast capillary electrophoresis separations."

Dr. Richard Joyce, Structural Elucidation Scientist at Pfizer (UK), commented: "It is vital to us to solve real-life identification problems in a dramatically reduced time: our joint development of SmartFormula 3D applied at maXis performance levels meets our goal of a one-shot Molecular Formula Machine."

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.

Bruker Daltonik GmbH
Fahrenheitstr. 4
28359 Bremen, Germany

http://www.measurementdevices.com/index.php?name=News&file=article&sid=1324